Keyphrases
3-group
5%
Aborted Cardiac Arrest
5%
Adverse Outcomes
5%
Aldosterone Antagonists
5%
Atrial Fibrillation
100%
Cardiac Function
5%
Cardiovascular Mortality
5%
Cardiovascular Risk
5%
Confidence Interval
10%
Early Risk
10%
Hazard Ratio
10%
Heart Failure
5%
Heart Failure Hospitalization
5%
Heart Failure with Preserved Ejection Fraction (HFpEF)
100%
North America
5%
Post-randomization
21%
Response-outcome
5%
Risk-adjusted
5%
South America
5%
Spironolactone
31%
TOPCAT
10%
TOPCAT Trial
100%
Treatment Effect
5%
Treatment Response
10%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Outcome
5%
Aldosterone Antagonist
5%
Atrial Fibrillation
100%
Cardiovascular Mortality
5%
Cardiovascular Risk
5%
Congestive Heart Failure
10%
Heart Arrest
5%
Heart Failure with Preserved Ejection Fraction
100%
Spironolactone
31%